Rein Therapeutics Inc. (RNTX) News
Follow Rein Therapeutics Inc. (RNTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
RNTX advances LTI-03 in Phase 2 IPF trials, enrolls RENEW
RNTX says its inhaled peptide LTI-03 has shown favorable safety and biomarker activity, and is advancing in Phase 2 for IPF. The RENEW Phase 2 trial is now enrolling, with data expected in late 2026.
EQUITY | Sep 06, 2026, 07:27 PM UTC
L
Rein Therapeutics publishes LTI-03 presentation, Phase 2 trial enrolling
Rein Therapeutics published an LTI-03 presentation citing Phase 1b biomarker activity, preclinical antifibrotic data and that the RENEW Phase 2 trial is now enrolling.
REGULATION | Sep 04, 2026, 08:33 PM UTC
L
Rein Therapeutics to present late-breaking poster at ERS 2026 congress
Rein Therapeutics said it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress.
GEOPOLITICS | Sep 04, 2026, 12:07 PM UTC
H
RNTX - Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
RNTX - Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
GEOPOLITICS | Sep 04, 2026, 12:00 PM UTC
L
Rein Therapeutics to present at September investor conferences
Rein Therapeutics (RNTX) said Brian Windsor, President and CEO, will present at upcoming September investor conferences.
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
Rein Therapeutics to present at September investor conferences
Rein Therapeutics (RNTX) plans to present at upcoming September investor conferences.
EQUITY | Sep 03, 2026, 08:01 PM UTC
L
Rein Therapeutics discloses failure to meet continued listing rule
Rein Therapeutics said it failed to satisfy a continued listing rule or standard.
EQUITY | Aug 27, 2026, 08:16 PM UTC
H
Rein Therapeutics gets FDA Fast Track for LTI-03 in IPF
Rein Therapeutics (RNTX) says the U.S. FDA granted Fast Track Designation for LTI-03 in idiopathic pulmonary fibrosis.
REGULATION | Aug 20, 2026, 12:00 PM UTC
L
Rein Therapeutics reports Q2 2026 results, business update
Rein Therapeutics (RNTX) reports second quarter 2026 financial results and provides a business update.
EARNINGS | Aug 14, 2026, 10:44 AM UTC
M
Rein Therapeutics Publishes LTI-03 Clinical Data
Rein Therapeutics publishes clinical data in Nature Communications
EQUITY | Aug 04, 2026, 12:01 PM UTC